Xenoview is a drug owned by Polarean Inc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Xenoview's patents will be open to challenges from 23 December, 2026. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 29, 2035. Details of Xenoview's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11052161 | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Dec, 2035
(11 years from now) | Active |
| US10583205 | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Feb, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Xenoview's patents.
Latest Legal Activities on Xenoview's Patents
Given below is the list of recent legal activities going on the following patents of Xenoview.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Aug, 2023 | US10583205 |
| Post Issue Communication - Certificate of Correction | 09 Nov, 2021 | US11052161 |
| Email Notification Critical | 04 Nov, 2021 | US11052161 |
| Mail Certificate of Correction Memo | 03 Nov, 2021 | US11052161 |
| Certificate of Correction Memo | 01 Nov, 2021 | US11052161 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Jul, 2021 | US11052161 |
| Recordation of Patent Grant Mailed Critical | 06 Jul, 2021 | US11052161 |
| Email Notification Critical | 17 Jun, 2021 | US11052161 |
| Issue Notification Mailed Critical | 16 Jun, 2021 | US11052161 |
| Dispatch to FDC | 01 Jun, 2021 | US11052161 |
FDA has granted several exclusivities to Xenoview. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Xenoview, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Xenoview.
Exclusivity Information
Xenoview holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Xenoview's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2027 |
US patents provide insights into the exclusivity only within the United States, but Xenoview is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Xenoview's family patents as well as insights into ongoing legal events on those patents.
Xenoview's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Xenoview's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 29, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xenoview Generics:
There are no approved generic versions for Xenoview as of now.
About Xenoview
Xenoview is a drug owned by Polarean Inc. It is used for a variety of conditions such as depression, anxiety, and nerve pain. Xenoview uses Xenon Xe-129 Hyperpolarized as an active ingredient. Xenoview was launched by Polarean in 2022.
Approval Date:
Xenoview was approved by FDA for market use on 23 December, 2022.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Xenoview is 23 December, 2022, its NCE-1 date is estimated to be 23 December, 2026.
Active Ingredient:
Xenoview uses Xenon Xe-129 Hyperpolarized as the active ingredient. Check out other Drugs and Companies using Xenon Xe-129 Hyperpolarized ingredient
Treatment:
Xenoview is used for a variety of conditions such as depression, anxiety, and nerve pain.
Dosage:
Xenoview is available in gas form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | GAS | Prescription | INHALATION |